417 related articles for article (PubMed ID: 25257732)
21. Behavior abnormality following intravenous immunoglobulin treatment in patients with primary antibody deficiencies.
Saroukhani S; Aghamohammadi A; Mahmoudi-Gharaei J; Abolhassani H; Cheraghi T; Imanzaeh A; Moazzami K; Parvaneh N; Rezaei N
Hum Psychopharmacol; 2010 Jul; 25(5):419-22. PubMed ID: 20589928
[TBL] [Abstract][Full Text] [Related]
22. IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin.
Torabi Sagvand B; Mirminachi B; Abolhassani H; Shokouhfar T; Keihanian T; Amirzargar A; Mahdaviani A; Aghamohammadi A
Allergol Immunopathol (Madr); 2015; 43(4):403-8. PubMed ID: 25201762
[TBL] [Abstract][Full Text] [Related]
23. Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.
Costa-Carvalho BT; Sullivan KE; Fontes PM; Aimé-Nobre F; Gonzales IGS; Lima ES; Granato C; de Moraes-Pinto MI
J Clin Immunol; 2018 Jul; 38(5):628-634. PubMed ID: 30006913
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
26. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
27. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.
Frenzel W; Wietek S; Svae TE; Debes A; Svorc D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):847-855. PubMed ID: 27719744
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.
Singh-Grewal D; Kemp A; Wong M
Arch Dis Child; 2006 Aug; 91(8):651-4. PubMed ID: 16638785
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
30. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
[TBL] [Abstract][Full Text] [Related]
31. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
32. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
34. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
35. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
[TBL] [Abstract][Full Text] [Related]
36. Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141).
Dash C; Gascoigne E; Gillanders K; Gooi H
PLoS One; 2015; 10(7):e0131565. PubMed ID: 26222441
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
[TBL] [Abstract][Full Text] [Related]
38. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
[TBL] [Abstract][Full Text] [Related]
39. [Personal experience with replacement therapy with intravenous gamma globulin].
Litzman J; Lokaj J; Stikarovská D; Mayer J; Thon V; Eibl MM
Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
[TBL] [Abstract][Full Text] [Related]
40. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
Berger M; Cunningham-Rundles C; Bonilla FA; Melamed I; Bichler J; Zenker O; Ballow M
J Clin Immunol; 2007 Sep; 27(5):503-9. PubMed ID: 17479360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
